Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q3 EPS of $1.05, $0.15 better than the analyst estimate of $0.90. Revenue for the quarter came in at $384 million versus the consensus estimate of $371.8 million.

Idexx Laboratories, Inc. sees FY2014 EPS of $3.85-$3.90, versus the consensus of $3.82.

Idexx Laboratories, Inc. sees FY2015 EPS of $4.38-$4.48, versus the consensus of $4.33.

"We achieved exceptional growth across our business in the third quarter, reflecting benefits from our investments in our global commercial capability and innovation pipeline. Normalized CAG Diagnostics recurring revenues grew organically over 11% in the US and 15% in international markets, supported by strong gains across our modalities. Our instrument placements were also outstanding, setting the foundation for sustained strong growth in highly durable CAG Diagnostics recurring revenues. In the quarter we placed over 650 Catalysts and 750 hematology instruments globally, as well as 3,200 SNAP Pro® Mobile Devices. We look forward to building on this momentum with customer shipments of Catalyst One beginning November 3rd. Catalyst One expands the market for our highly differentiated Catalyst technology with a significantly lower entry price," said Jonathan Ayers, the Company's Chairman and Chief Executive Officer.

For earnings history and earnings-related data on Idexx Laboratories, Inc. (IDXX) click here.